JCAR017

DRUG6 trials

Conditions

Chronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaFollicular LymphomaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMantle Cell LymphomaMultiple Myeloma

Phase 1

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

CompletedNCT03310619

CelgeneLymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin

Start: 2017-12-20End: 2023-02-15Updated: 2024-04-04

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

TerminatedNCT03743246

CelgeneLymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Start: 2018-10-17End: 2024-01-26Updated: 2024-08-15

Phase 2

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

CompletedNCT03484702

CelgeneLymphoma, Non-Hodgkin

Start: 2018-06-05End: 2023-12-15Updated: 2024-12-27

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruitingNCT04245839

CelgeneLymphoma, Non-Hodgkin

Start: 2020-07-14End: 2031-09-30Target: 276Updated: 2025-11-05

Phase 3

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

CompletedNCT03575351

CelgeneLymphoma, Non-Hodgkin

Start: 2018-10-23End: 2023-10-23Updated: 2025-08-03

Unknown Phase

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

TerminatedNCT03436771

Juno Therapeutics, a Subsidiary of CelgeneChronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma +3

Start: 2018-02-19End: 2018-07-20Updated: 2020-05-04

Advances in Therapy2026-05-15

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

2026-04-27

Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study

Blood2025-11-03

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Blood2025-11-03

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Blood2025-11-03

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Blood2025-11-03

INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Blood2025-11-03

Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma

Leukemia & lymphoma/Leukemia and lymphoma2025-07-24

Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.

Journal of Clinical Oncology2025-05-28

Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU).

Journal of Clinical Oncology2025-05-28

Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma.

2025-03-055 citations

Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model

BMJ Open2025-01-012 citations

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood2024-11-056 citations

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood2024-11-056 citations

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Blood2024-11-052 citations

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Blood2024-11-051 citations

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Blood2024-11-051 citations

Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Blood2024-11-051 citations

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood2024-11-051 citations

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Blood2024-11-051 citations

34 more papers not shown

JCAR017

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Unknown Phase

Related Papers